Rubinstein Julie reported option exercise involving 11,881 derivative units of Adaptive Biotechnologies Corp at $0.00 for $0 on Nov 6, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
President and COO
President and COO
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
11,881Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
58,990Direct
Trade date
Nov 6, 2026Option exercise
Filed
Nov 6, 2026, 7:24 PM ET1-day reporting delay
Accession
0001780664-26-000051Code M · Transaction 395377
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Sell4,000$25.78−$103,120Trade 395366
Nov 4, 2026Sell7,881$26.60−$209,634.60Trade 395367
Nov 5, 2026Sell5,926$26.10−$154,668.60Trade 395369
Nov 5, 2026Sell5,455$26.88−$146,630.40Trade 395370
Nov 5, 2026Sell500$27.70−$13,850Trade 395371
Nov 6, 2026Sell8,400$27.32−$229,488Trade 395373
Nov 6, 2026Sell3,481$27.88−$97,050.28Trade 395374
Nov 4, 2026Option exercise11,881$12.14$144,235.34Trade 395365
Nov 5, 2026Option exercise11,881$12.14$144,235.34Trade 395368
Nov 6, 2026Option exercise11,881$12.14$144,235.34Trade 395372
Nov 4, 2026Option exercise11,881$0.00$0Trade 395375
Nov 5, 2026Option exercise11,881$0.00$0Trade 395376
13 transaction rows in this filing. Joint filers share the same rows.

ADPT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADPT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −6.1%1w ago −4.8%1d ago −4.1%
Returns since7d +3.8%30d90d180d1y

Footnotes in full

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F6: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F7: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F8: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. F9: The option is fully vested and exercisable.